Author:
Hoang Nguyen Truong Duc,Hassan Ghmkin,Suehiro Tomoya,Mine Yuichi,Matsuki Tohru,Fujii Makiko
Abstract
AbstractBackgroundMalignant mesothelioma (MM) is an aggressive mesothelial cell cancer type linked mainly to asbestos inhalation. MM characterizes by rapid progression and resistance to standard therapeutic modalities such as surgery, chemotherapy, and radiotherapy. Our previous studies have suggested that tumor cell-derived connective tissue growth factor (CTGF) regulates the proliferation of MM cells as well as the tumor growth in mouse xenograft models.MethodsIn this study, we knock downed the bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) and CTGF in MM cells and investigated the relationship between both and their impact on the cell cycle and cell proliferation.ResultsThe knockdown of CTGF or BAMBI reduced MM cell proliferation. In contrast to CTGF knockdown which decreased BAMBI, knockdown of BAMBI increased CTGF levels. Knockdown of either BAMBI or CTGF reduced expression of the cell cycle regulators; cyclin D3, cyclin-dependent kinase (CDK)2, and CDK4. Further, in silico analysis revealed that higher BAMBI expression was associated with shorter overall survival rates among MM patients.ConclusionsOur findings suggest that BAMBI is regulated by CTGF promoting mesothelioma growth by driving cell cycle progression. Therefore, the crosstalk between BAMBI and CTGF may be an effective therapeutic target for MM treatment.
Funder
Start-up funding
Nozomi H Foundation funding
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference52 articles.
1. Neumann V, Löseke S, Nowak D, Herth FJ, Tannapfel A. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch Arztebl Int. 2013;110(18):319–26.
2. Cavone D, Caputi A, De Maria L, Cannone E, Mansi F, Birtolo F, et al. Epidemiology of Mesothelioma. Environments. 2019;6(7):1–18. https://doi.org/10.3390/environments6070076.
3. Amin W, Linkov F, Landsittel DP, Silverstein JC, Bashara W, Gaudioso C, et al. Factors influencing malignant mesothelioma survival: a retrospective review of the national mesothelioma virtual bank cohort. F1000Res. 2018;7:1184.
4. Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(2):129–42.
5. Zucali PA. Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S311–21.